• Je něco špatně v tomto záznamu ?

Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trial

KRH. Branch, GR. Dagenais, A. Avezum, J. Basile, I. Conget, WC. Cushman, P. Jansky, M. Lakshmanan, F. Lanas, LA. Leiter, P. Pais, N. Pogosova, PJ. Raubenheimer, L. Ryden, JE. Shaw, WHH. Sheu, T. Temelkova-Kurktschiev, MA. Bethel, HC. Gerstein, R....

. 2022 ; 24 (10) : 1805-1812. [pub] 20220920

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu randomizované kontrolované studie, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22033168
E-zdroje Online Plný text

NLK Medline Complete (EBSCOhost) od 2000-03-01 do Před 1 rokem
Wiley Free Content od 1999 do Před 1 rokem

Odkazy

PubMed 36073143
DOI 10.1002/ejhf.2670
Knihovny.cz E-zdroje

AIMS: People with diabetes are at high risk for cardiovascular events including heart failure (HF). We examined the effect of the glucagon-like peptide 1 agonist dulaglutide on incident HF events and other cardiovascular outcomes in those with or without prior HF in the randomized placebo-controlled Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial. METHODS AND RESULTS: The REWIND major adverse cardiovascular event (MACE) outcome was the first occurrence of a composite endpoint of non-fatal myocardial infarction, non-fatal stroke, or death from cardiovascular causes (including unknown causes). In this post-hoc analysis, a HF event was defined as an adjudication-confirmed hospitalization or urgent evaluation for HF. Of the 9901 participants studied over a median follow-up of 5.4 years, 213/4949 (4.3%) randomly assigned to dulaglutide and 226/4952 (4.6%) participants assigned to placebo experienced a HF event (hazard ratio [HR] 0.93, 95% confidence interval [CI] 0.77-1.12; p = 0.456). In the 853 (8.6%) participants with HF at baseline, there was no change in either MACE or HF events with dulaglutide as compared to participants without HF (p = 0.44 and 0.19 for interaction, respectively). Combined cardiovascular death and HF events were marginally reduced with dulaglutide compared to placebo (HR 0.88, 95% CI 0.78-1.00; p = 0.050) but unchanged in patients with and without HF at baseline (p = 0.31). CONCLUSIONS: Dulaglutide was not associated with a reduction in HF events in patients with type 2 diabetes regardless of baseline HF status over 5.4 years of follow-up.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22033168
003      
CZ-PrNML
005      
20230131151601.0
007      
ta
008      
230120s2022 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1002/ejhf.2670 $2 doi
035    __
$a (PubMed)36073143
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Branch, Kelley R H $u University of Washington Heart Institute, Seattle, WA, USA $1 https://orcid.org/0000000323626498
245    10
$a Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trial / $c KRH. Branch, GR. Dagenais, A. Avezum, J. Basile, I. Conget, WC. Cushman, P. Jansky, M. Lakshmanan, F. Lanas, LA. Leiter, P. Pais, N. Pogosova, PJ. Raubenheimer, L. Ryden, JE. Shaw, WHH. Sheu, T. Temelkova-Kurktschiev, MA. Bethel, HC. Gerstein, R. Chinthanie, JL. Probstfield
520    9_
$a AIMS: People with diabetes are at high risk for cardiovascular events including heart failure (HF). We examined the effect of the glucagon-like peptide 1 agonist dulaglutide on incident HF events and other cardiovascular outcomes in those with or without prior HF in the randomized placebo-controlled Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial. METHODS AND RESULTS: The REWIND major adverse cardiovascular event (MACE) outcome was the first occurrence of a composite endpoint of non-fatal myocardial infarction, non-fatal stroke, or death from cardiovascular causes (including unknown causes). In this post-hoc analysis, a HF event was defined as an adjudication-confirmed hospitalization or urgent evaluation for HF. Of the 9901 participants studied over a median follow-up of 5.4 years, 213/4949 (4.3%) randomly assigned to dulaglutide and 226/4952 (4.6%) participants assigned to placebo experienced a HF event (hazard ratio [HR] 0.93, 95% confidence interval [CI] 0.77-1.12; p = 0.456). In the 853 (8.6%) participants with HF at baseline, there was no change in either MACE or HF events with dulaglutide as compared to participants without HF (p = 0.44 and 0.19 for interaction, respectively). Combined cardiovascular death and HF events were marginally reduced with dulaglutide compared to placebo (HR 0.88, 95% CI 0.78-1.00; p = 0.050) but unchanged in patients with and without HF at baseline (p = 0.31). CONCLUSIONS: Dulaglutide was not associated with a reduction in HF events in patients with type 2 diabetes regardless of baseline HF status over 5.4 years of follow-up.
650    _2
$a lidé $7 D006801
650    12
$a diabetes mellitus 2. typu $x komplikace $x farmakoterapie $x epidemiologie $7 D003924
650    _2
$a hypoglykemika $x terapeutické užití $x škodlivé účinky $7 D007004
650    12
$a srdeční selhání $x farmakoterapie $x epidemiologie $x chemicky indukované $7 D006333
650    _2
$a výsledek terapie $7 D016896
650    _2
$a inkretiny $x terapeutické užití $7 D054795
650    12
$a kardiovaskulární nemoci $x epidemiologie $7 D002318
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Dagenais, Gilles R $u Institut Universitaire de Cardiologie et Pneumologie de Québec, Université Laval, Québec City, Québec, Canada $1 https://orcid.org/0000000245092004
700    1_
$a Avezum, Alvaro $u International Research Center, Hospital Alemão Oswaldo Cruz, São Paulo, Brazil $1 https://orcid.org/0000000230736890
700    1_
$a Basile, Jan $u Medical University of South Carolina, Ralph H Johnson VA Medical Center, Charleston, SC, USA $1 https://orcid.org/0000000223027084
700    1_
$a Conget, Ignacio $u Endocrinology and Nutrition Department, Hospital Clínic i Universitari, Barcelona, Spain $1 https://orcid.org/0000000255325449
700    1_
$a Cushman, William C $u University of Tennessee Health Science Center, Memphis, TN, USA $1 https://orcid.org/0000000171622972
700    1_
$a Jansky, Petr $u University Hospital Motol, Prague, Czech Republic
700    1_
$a Lakshmanan, Mark $u Eli Lilly & Co, Indianapolis, IN, USA $1 https://orcid.org/0000000265789570
700    1_
$a Lanas, Fernando $u Universidad de La Fontera, Temuco, Chile $1 https://orcid.org/0000000335959759
700    1_
$a Leiter, Lawrence A $u Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada $1 https://orcid.org/0000000210406229
700    1_
$a Pais, Prem $u St. John's Research Institute, Bangalore, India $1 https://orcid.org/0000000159853137
700    1_
$a Pogosova, Nana $u National Medical Research Center of Cardiology, Moscow, Russia $1 https://orcid.org/000000024165804X
700    1_
$a Raubenheimer, Peter J $u Division of Endocrinology, University of Cape Town, Cape Town, South Africa $1 https://orcid.org/0000000254161286
700    1_
$a Ryden, Lars $u Department of Medicine K2, Karolinska Institute, Stockholm, Sweden $1 https://orcid.org/0000000333543063
700    1_
$a Shaw, Jonathan E $u Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia $1 https://orcid.org/0000000261872203
700    1_
$a Sheu, Wayne H H $u Division of Endocrinology and Metabolism, Taipei Veterans General Hospital, Taipei, Taiwan $1 https://orcid.org/0000000288058340
700    1_
$a Temelkova-Kurktschiev, Theodora $u Robert Koch Medical Center, Sofia, Bulgaria $1 https://orcid.org/0000000246931068
700    1_
$a Bethel, M Angelyn $u Eli Lilly & Co, Indianapolis, IN, USA
700    1_
$a Gerstein, Hertzel C $u Population Health Research Institute, Hamilton Health Sciences and McMaster University, Hamilton, Ontario, Canada $1 https://orcid.org/0000000180722836
700    1_
$a Chinthanie, Ramasundarahettige $u Population Health Research Institute, Hamilton Health Sciences and McMaster University, Hamilton, Ontario, Canada
700    1_
$a Probstfield, Jeffrey L $u University of Washington Heart Institute, Seattle, WA, USA $1 https://orcid.org/0000000248999971
773    0_
$w MED00006634 $t European journal of heart failure $x 1879-0844 $g Roč. 24, č. 10 (2022), s. 1805-1812
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36073143 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230120 $b ABA008
991    __
$a 20230131151557 $b ABA008
999    __
$a ok $b bmc $g 1891749 $s 1184503
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2022 $b 24 $c 10 $d 1805-1812 $e 20220920 $i 1879-0844 $m European journal of heart failure $n Eur J Heart Fail $x MED00006634
LZP    __
$a Pubmed-20230120

Najít záznam

Citační ukazatele

Možnosti archivace